Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Saved in:
| Title: | Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. |
|---|---|
| Authors: | Wang G; Washington University St Louis School of Medicine St. Louis Missouri USA., Li Y; Washington University St Louis School of Medicine St. Louis Missouri USA., Xiong C; Washington University St Louis School of Medicine St. Louis Missouri USA., McDade E; Washington University St Louis School of Medicine St. Louis Missouri USA., Clifford DB; Washington University St Louis School of Medicine St. Louis Missouri USA., Mills SL; Washington University St Louis School of Medicine St. Louis Missouri USA., Santacruz AM; Washington University St Louis School of Medicine St. Louis Missouri USA., Aschenbrenner AJ; Washington University St Louis School of Medicine St. Louis Missouri USA., Hassenstab J; Washington University St Louis School of Medicine St. Louis Missouri USA., Benzinger TLS; Washington University St Louis School of Medicine St. Louis Missouri USA., Gordon BA; Washington University St Louis School of Medicine St. Louis Missouri USA., Fagan AM; Washington University St Louis School of Medicine St. Louis Missouri USA., Coalier KA; Washington University St Louis School of Medicine St. Louis Missouri USA., Libre-Guerra JJ; Washington University St Louis School of Medicine St. Louis Missouri USA., McCullough A; Washington University St Louis School of Medicine St. Louis Missouri USA., Joseph-Mathurin N; Washington University St Louis School of Medicine St. Louis Missouri USA., Chen CD; Washington University St Louis School of Medicine St. Louis Missouri USA., Mummery C; University College London London UK., Wendelberger BA; Berry Consultants LLC Austin Texas USA., Gauthier S; McGill University Centre for Studies on Aging in Montreal Montreal Quebec Canada., Masellis M; University of Toronto Sunnybrook Health Sciences Centre Toronto Ontario Canada., Holdridge KC; Eli Lilly and Company Indianapolis Indiana USA., Yaari R; Eli Lilly and Company Indianapolis Indiana USA., Chatterjee S; Eli Lilly and Company Indianapolis Indiana USA., Sims J; Eli Lilly and Company Indianapolis Indiana USA., Delmar P; F. Hoffmann-La Roche, Ltd. Basel Switzerland., Kerchner GA; F. Hoffmann-La Roche, Ltd. Basel Switzerland., Bittner T; F. Hoffmann-La Roche, Ltd. Basel Switzerland., Hofmann C; F. Hoffmann-La Roche, Ltd. Basel Switzerland., Bateman RJ; Washington University St Louis School of Medicine St. Louis Missouri USA. |
| Corporate Authors: | DIAN‐TU Study Team |
| Source: | Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2022 Nov 03; Vol. 14 (1), pp. e12367. Date of Electronic Publication: 2022 Nov 03 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101654604 Publication Model: eCollection Cited Medium: Print ISSN: 2352-8729 (Print) Linking ISSN: 23528729 NLM ISO Abbreviation: Alzheimers Dement (Amst) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2352-8729 |
|---|---|
| DOI: | 10.1002/dad2.12367 |
